Prior Authorization Required for Listed Codes

Prior authorization is required for listed CPT and HCPCS codes related to intramuscular autologous bone marrow cell therapy and associated procedures. Claims for these services should be reviewed prior to authorization to ensure the intervention and indication align with policy intent.

• Affected CPT/HCPCS codes include 0263T, 0264T, 0265T and related procedure codes (e.g., 64910–64913). HCPCS C9782 is listed as not covered for the indications in this Clinical Policy Bulletin.

Prior Authorization — Required Documentation

Given the investigational status and mixed evidence base across indications, prior authorization must include submission of complete clinical documentation: indication, prior therapies attempted, rationale for cell therapy, and detailed procedural plans (route of administration, cell source, cell dose, and processing methods).

• Document clinical indication and reason standard therapies were insufficient or contraindicated.
• Provide prior treatment history and confirmation that standard/optimal therapies and revascularization (when applicable) were attempted or are not viable.
• Include informed consent acknowledging investigational status and potential risks.

Prior Authorization Requirements

Prior authorization requests should document protocol-specified dosing, timing, and delivery routes consistent with trial evidence when applicable. For stem cell transplantation and other investigational cell therapies, authorization is expected only with submission of clinical trial evidence or detailed justification and safety monitoring plans.

• Provide cell dose (total nucleated cells or MSC count), frequency, and preparation/processing method.
• Specify timing relative to index event (e.g., days post-AMI) and route (intramyocardial, intracoronary, intra-arterial, intravenous, intrathecal, intra-articular).
• Attach trial protocol or peer-reviewed evidence when treatment mirrors a research protocol.

Prior Authorization for Stem Cell Transplantation

Stem cell transplantation procedures (autologous or allogeneic) for indications described in this bulletin are investigational for many conditions; prior authorization for such transplants will require submission of clinical trial data or substantial peer-reviewed evidence to support safety and efficacy.

• For CLAD, MSC dosing in trials (e.g., 2 x 10^6 cells/kg IV) and monitoring schedules should be provided.
• For GVHD prophylaxis/treatment and other indications, include trial identifiers and outcomes if claiming investigational coverage.

Clinical Eligibility and Dosing Must Be Documented

Clinical eligibility criteria and dosing used in trials must be documented in authorization requests. Trials frequently specified numeric thresholds, disease severity scores, and stability on standard therapy prior to enrollment; these must be confirmed in clinical documentation.

• Examples of eligibility metrics: LVEF thresholds, EDSS range for MS (eg, 3.0–6.5), BOS grade for CLAD, Rutherford/Fontaine class for PAD/CLI.
• Document prior stabilization on guideline-directed medical therapy (e.g., ≥3 months of optimized heart failure therapy where applicable).
• Record exact cell dose, viability, characterization (phenotype), and passage/expansion details for culture-expanded products.

Prior Authorization for Investigational Cell Therapies

Requests for investigational cell therapies should include the specific indication, supporting clinical trial evidence or rationale, prior therapy failures, and informed consent acknowledging investigational use. In the absence of convincing evidence, authorization may be denied.

• Include references to randomized controlled trials or registries supporting proposed use when available.
• If therapy is part of a clinical trial, include trial sponsor, identifier, and IRB approval documentation.
• For off-protocol compassionate use, include multidisciplinary review and justification.

Non-Covered Codes

Certain CPT/HCPCS and ICD-10 codes are identified as not covered for the indications listed in this bulletin. Providers should not bill or expect coverage for these codes for investigational indications without prior authorization and supporting evidence.

• Not covered CPT codes include 0263T, 0264T, 0265T for indications listed in this CPB unless otherwise authorized.
• HCPCS code C9782 is listed as not covered for the specified indications.
• ICD-10 diagnoses listed (e.g., G35, K50.*, H35.32, I00–I99) are noted as examples of conditions for which procedures are considered investigational per this policy.

Evidence-Limited Interventions

Many interventions described are evidence-limited or investigational due to small trial sizes, inconsistent results, high risk of bias, or lack of durable clinically meaningful outcomes. Authorization decisions will weigh the strength and quality of available evidence.

• Examples: intramuscular autologous BMMNCs for CLI have only small RCTs with mixed outcomes.
• Knee osteoarthritis MSC injections show heterogeneity and inconclusive high-level evidence; conservative therapy recommended first.
• Tendon disorder studies are low-level (level 4) with insufficient evidence.

Evidence-Based Denial Risk

Where randomized trials failed to demonstrate primary efficacy or showed inconsistent results, submissions lacking compelling new evidence may be denied. Examples include several post‑AMI BMC trials that did not improve LVEF versus placebo.

• LateTIME, TIME, and other RCTs showed no consistent improvement in global or regional LV function at 6 months in many cohorts.
• Negative or neutral RCT outcomes should be addressed with robust justification if requesting coverage.
• Absence of improvement in primary endpoints (e.g., LVEF, major amputation reduction) increases denial risk.

Efficacy Not Demonstrated in Some Trials

Some trials demonstrated no efficacy on primary endpoints or only modest/uncertain benefits; authorization should be contingent on stronger evidence or enrollment in approved clinical trials.

• Phase III and large RCTs (e.g., Nair et al 2015, JUVENTAS) reported no significant benefit for certain AMI and CLI endpoints.
• Documented lack of durable mortality or morbidity benefit may prompt noncoverage decisions.

Insufficient Evidence May Trigger Noncoverage

Insufficient or low-quality evidence (small RCTs, pilot studies, high risk of bias, heterogenous methods) may trigger noncoverage for routine clinical use. Coverage may be limited to clinical trial settings or require additional documentation.

• Procedures with only early-phase, uncontrolled, or small cohort data (e.g., many neurologic and ophthalmologic indications) are considered investigational.
• When evidence is limited, require enrollment in a registry or trial and submission of outcome data for reconsideration.

Inconclusive Efficacy and Risk of Denial

When evidence is inconclusive, including high placebo response rates or trial design limitations, authorization is less likely outside of approved research protocols. High placebo responses (e.g., AMDC‑USR trial) can obscure efficacy and affect coverage decisions.

• AMDC-USR showed unexpectedly high placebo response (90%), limiting efficacy interpretation.
• Requests should include justification for patient selection and outcome measures that mitigate placebo effects.

Evidence Insufficiency Risk

Limited or inconsistent evidence across indications increases the risk that coverage will be denied unless robust, high-quality data or trial participation is documented. For many indications evidence remains preliminary and exploratory.

• Small sample sizes, lack of control groups, variable dosing and delivery methods contribute to evidence insufficiency.
• Provide long-term follow-up data and safety monitoring plans when available to support authorization.

Step Therapy and Optimization Expectations

No additional step therapy requirements are specified in this section beyond the expectation to optimize or attempt standard therapies prior to investigational cell-based interventions.

• Providers must document that standard/conservative therapies were optimized prior to requesting authorization.
• If applicable, document attempts at revascularization or that the patient is not a candidate for revascularization.

Optimize Standard Therapy First; Consider Revascularization/Conservative Therapy

Optimize standard or conservative therapy before considering investigational cell interventions. For PAD/CLI, standard surgical or endovascular revascularization is preferred; for knee OA and other conditions, conservative measures should be tried first.

• Document failure or contraindication of guideline-directed medical therapy (eg, optimal heart failure therapy for ≥3 months).
• For PAD/CLI, include documentation of prior revascularization attempts or rationale why revascularization is not feasible.
• For knee OA, document trials of conservative management (physical therapy, medications, injections) prior to MSC injection requests.

Recommended Outcome Documentation

Recommended outcome and monitoring documentation should mirror clinical trial protocols where available: baseline and serial imaging, functional measures, validated quality‑of‑life instruments, and standardized adverse event monitoring.

• Cardiac outcomes: serial cardiac MRI or echocardiography (LVEF, LV volumes EDV/ESV), SPECT perfusion where used, 6‑minute walk test, NYHA/CCS class, and QoL instruments.
• Peripheral vascular outcomes: ABI, rest pain scores, Rutherford/Fontaine classification, ulcer healing assessments, and amputation-free survival.
• Neurologic/functional outcomes: EDSS, mRS, MRI with/without gadolinium, EEG/cognitive testing as applicable.

Required Clinical Documentation

Required clinical documentation for authorization includes baseline and follow-up objective measures, procedural details, cell product characterization, and safety monitoring plans consistent with trial methodologies.

• Procedure details: delivery route, electromechanical mapping if used, imaging or guidance modality, and peri-procedural monitoring.
• Cell product: cell type, total dose, viability, phenotype/markers, culture/expansion method, and lot/repository identifiers.
• Follow-up schedule: timing of imaging and functional assessments, planned adverse event surveillance, and long‑term outcome reporting.

Required Clinical Measurements and Follow-Up

Trials emphasize specific clinical measurements and follow-up intervals; authorization and post-procedure coverage may require adherence to these measurements to document effectiveness and safety.

• Cardiac: LVEF, LVEDV/LVESV, infarct size, and method of measurement (MRI preferred when trial used MRI).
• Peripheral: ABI, ulcer area, rest pain scale, and amputation outcomes at defined timepoints.
• Cell therapy specifics: dose administered, route, lot numbers, and any repeat administration schedules.

Suggested Clinical Measures to Document

Suggested clinical measures to document depend on indication but generally include validated functional scales, imaging, wound assessments, and quality-of-life instruments used in trials.

• Cardiac: 6-minute walk distance, CCS/NYHA class, Seattle Angina Questionnaire, Minnesota Living with Heart Failure score.
• Peripheral: Rutherford/Fontaine class, ABI, transcutaneous oxygen pressure, ulcer healing metrics.
• Voice/vocal fold: Voice Handicap Index (VHI), high-speed laryngoscopy and phonation pressure threshold.

Trial Documentation and Monitoring Expectations

Trial documentation and monitoring expectations should include protocol-specified inclusion/exclusion criteria, objective outcome assessments, cell-product testing, and safety monitoring consistent with the evidence base cited in this policy.

• Include trial inclusion criteria analogues (e.g., LVEF thresholds, disease chronicity, prior therapy failure).
• Specify objective endpoints and timing (eg, 3‑, 6‑, 12‑month MRI or functional assessments).
• Adverse event reporting plan and long-term follow-up schedule (eg, 1 year or longer when trials reported such follow-up).

Trial Protocol and Follow-Up Documentation Elements

Authorization requests should include trial protocol elements where applicable: cell dose, route of administration, monitoring plan, and defined functional and imaging outcomes to support safety and efficacy claims.

• Provide electromechanical mapping or imaging guidance details for intramyocardial injections.
• List cell characterization and biorepository analyses if available (phenotypic and functional assays).
• Define outcome metrics and timepoints that mirror published trial endpoints.

Required Clinical Procedure and Outcome Documentation

Clinical procedure and outcome documentation must include procedural technique details, peri-procedural monitoring, and objective outcome measures used in clinical trials to substantiate claims of benefit and safety.

• Document left ventricular electromechanical mapping when used, precise injection sites, imaging guidance, and bone marrow harvest details.
• Report peri-procedural adverse events and 30‑day SAE composite outcomes when applicable.
• Provide pre- and post-procedure imaging and validated functional scores at defined intervals.

Policy References and Review History

Policy references, review history, and administrative details are provided in the Clinical Policy Bulletin. Providers should consult the CPB review history and definitions for clarifications; bulletin content does not guarantee coverage and may change.

• Effective date: 2002-03-12; Next review date listed on the CPB.
• Review history and definitions links are available in the bulletin for operational details.
• Clinical Policy Bulletins are informational and do not constitute a coverage guarantee.